New CEOs for AdvanCell, Sonoma
Plus: U.K. biotech Mosaic continues to remake C-suite with CSO hire and updates from Société Générale, CG Oncology, Mesoblast, 4D Molecular
Philina Lee is succeeding Andrew Adamovich as CEO of AdvanCell Pty. Ltd., with a mandate to lead the Australian radiopharmaceutical company’s expansion in the U.S. Lee, who will be based at the company’s new stateside HQ in the Boston/Cambridge area, joins the company from Blueprint Medicines Corp., where she was chief commercial officer. Lee also served on the board of radiopharma Fusion Pharmaceuticals Inc. and held senior roles at alpha therapy company Algeta ASA. Adamovich, AdvanCell’s founder and longtime CEO, will become managing director, Australia, and remain on the board, which Lee will join. AdvanCell was featured in a BioCentury Emerging Company Profile last week. Blueprint was recently acquired by Sanofi (Euronext:SAN; NASDAQ:SNY).
Stephen Dilly is taking over as CEO of Sonoma Biotherapeutics Inc. as current CEO and founder Jeff Bluestone shifts to an advisory role while retaining his board seat. Dilly, who joins the San Francisco Bay Area Treg company’s board, is chair of Codexis Inc., where he had been president and CEO...